- Trials with a EudraCT protocol (23)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
23 result(s) found for: Signal to noise ratio.
Displaying page 1 of 2.
EudraCT Number: 2004-004084-29 | Sponsor Protocol Number: MultiH/BRA/900 | Start Date*: 2005-03-18 |
Sponsor Name:Bracco ALTANA Pharma GmbH | ||
Full Title: Intraindividual cross-over study to compare 1.5-tesla and 3.0-tesla MRI with 0.05+0.05 mmol/kgbw MultiHance® in patients with Myocardial Infarction | ||
Medical condition: myocardial infarction | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-004700-20 | Sponsor Protocol Number: 2104-02 | Start Date*: 2005-03-11 |
Sponsor Name:Epix Pharmaceuticals, Inc. | ||
Full Title: Phase II Feasibility study of safety and efficacy of Magnetic Resonance Imaging of Thrombi with EP-2104R in the detection in Venous Thromboembolism (VTE) | ||
Medical condition: Detection of venous thromboembolism | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2004-004701-23 | Sponsor Protocol Number: 2104-03 | Start Date*: 2005-03-14 |
Sponsor Name:Epix Pharmaceuticals, Inc. | ||
Full Title: Phase II feasibility study to evaluate the safety and efficacy of EP-2104R for Magnetic Resonance Imaging of thrombi in the arterial vasculature and cardiac chambers | ||
Medical condition: Detection of thrombi in the arterial vasculature and cardiac chambers | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) DE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2006-007042-18 | Sponsor Protocol Number: CHD Vasovist | Start Date*: 2007-03-08 | |||||||||||
Sponsor Name:Kings College London [...] | |||||||||||||
Full Title: Improved Diagnosis of Congenital Heart Disease by MRI using Vasovist - CHD Vasovist | |||||||||||||
Medical condition: Congenital Heart Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-021526-36 | Sponsor Protocol Number: LMU_Rad_MR_GadoMRA01 | Start Date*: 2011-04-07 | |||||||||||
Sponsor Name:Klinikum der Universität München | |||||||||||||
Full Title: Dynamic and high-resolution MR angiography of the supraaortic vessels at 3 Tesla: Performance of Gadobutrol (Gadovist) in comparison to Gedobenate Dimeglumine (Multihance) and Gadoterate Meglumine ... | |||||||||||||
Medical condition: Supraaortic vessel disease; suspicion or proven carotid artery stenosis / stenoses | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-022570-13 | Sponsor Protocol Number: GAD-1140-WIL-0020-I | Start Date*: Information not available in EudraCT |
Sponsor Name:Medizinsiche Fakultät der Technischen Universität München | ||
Full Title: Gadovit-Studie Intraindividueller Vergleich der diagnostischen Wertigkeit von delayed-enhancement imaging mit Gadobutrol (Gadovist®) versus Gadobenat Dimeglumin (Multihance®) mittels einer MRT Bi... | ||
Medical condition: Rupture of a thrombotic plaque within a coronary artery leads to a complete or incomplete occlusion of the vessel with subsequent ischemia in the affected myocardium. If not revascularised within ... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-006135-29 | Sponsor Protocol Number: PH-107 | Start Date*: 2012-09-03 | |||||||||||
Sponsor Name:Bracco Imaging S.p.A. | |||||||||||||
Full Title: PHASE IV, DOUBLE-BLIND, MULTI-CENTER, RANDOMIZED, CROSSOVER STUDY TO COMPARE 0.1 mmol/kg OF PROHANCE® WITH 0.1 mmol/kg OF GADOVIST®/GADAVIST™ IN MAGNETIC RESONANCE IMAGING (MRI) OF THE BRAIN (TRUTH) | |||||||||||||
Medical condition: Have confirmed or are highly suspected of brain disease likely to enhance as determined by the following: clinical/neurological symptomatology; diagnostic testing, such as CT or previous MRI exam... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-004176-21 | Sponsor Protocol Number: CMC-P005 | Start Date*: 2007-10-01 |
Sponsor Name:CMC Contrast AB c/o Öresund Health Care Management | ||
Full Title: Evaluation of the diagnostic efficacy of CMC-001 (MnCl2 tetrahydrate) in MR cholangiography in patients with suspected liver lesions. A randomised, parallel group, open-label Phase II trial. | ||
Medical condition: Liver lesions. CMC-001 is an orally administered contrast medium containing manganese (Mn) as the active imaging substance. Manganese is absorbed by the healthy parts of the liver and will thus cre... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2008-004991-28 | Sponsor Protocol Number: MD2008-MR-0602 | Start Date*: 2009-03-26 |
Sponsor Name:Medical Faculty Magdeburg | ||
Full Title: Assessment of focal liver lesions in fluoroscopic MR using Primovist and fast dynamic imaging sequences for interventional purposes | ||
Medical condition: The purpose of this study is to evaluate the potential of a better demarcation of liver lesions after injection of the hepatocyte specific contrast agent Gadoxetic acid (Primovist) with fast dynami... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-004895-39 | Sponsor Protocol Number: MR Perfusion With An Intravascular | Start Date*: 2009-02-26 | |||||||||||
Sponsor Name:King's College London | |||||||||||||
Full Title: Quantitative Assessment of Myocardial Perfusion with Magnetic Resonance Using an Intravascular Contrast Agent | |||||||||||||
Medical condition: Ischemic cardiomyopathy, with inducible ischemia and clinical indication to cardiac revascularization | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003128-22 | Sponsor Protocol Number: 1.1 | Start Date*: 2017-10-19 |
Sponsor Name:The University of Leeds | ||
Full Title: Intraoperative imaging of colon cancer using a fluorescent peptide (EMI-137) against the c-Met receptor | ||
Medical condition: Colon cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-003886-33 | Sponsor Protocol Number: MH-148 | Start Date*: 2014-02-28 | |||||||||||
Sponsor Name:Bracco Imaging S.p.A. | |||||||||||||
Full Title: PHASE IV, DOUBLE-BLIND, MULTI-CENTER, RANDOMIZED, TWO-ARM CROSSOVER STUDY TO COMPARE 0.1 mmol/kg OF MULTIHANCE® WITH 0.1 mmol/kg OF DOTAREM® AND 0.05 mmol/kg OF MULTIHANCE® WITH 0.1 mmol/kg OF DOTA... | |||||||||||||
Medical condition: Patients have confirmed or are highly suspected to have brain tumor(s) (primary or secondary), as determined by: • clinical/neurological symptomatology; • diagnostic testing, such as CT or previ... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-001582-33 | Sponsor Protocol Number: Er-01-Perf-Stroke | Start Date*: 2012-09-19 |
Sponsor Name:University Hospital Erlangen | ||
Full Title: Intraindividual cross-over comparison of Gadobutrol and Gadoterate enhanced combined DSC-MR-Perfusion and MR-Angiography in patients with cerebrovascular disease | ||
Medical condition: Patients with high grade carotid artery stenosis or acute cerebral ischemia | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-005498-21 | Sponsor Protocol Number: | Start Date*: 2012-07-12 |
Sponsor Name:Med. Univ. Wien, Univ. Klinik für Radiodiagnostik | ||
Full Title: Breast lesion detection and characterization at contrast-Enhanced MRI of the breast: comparison of gadoterate meglumine versus gadobenate dimeglumine at 3 Tesla | ||
Medical condition: the aim of this study is to intraindividually compare the use of equivalent doses of gadobenate dimeglumine (MultiHance, Bracco Imaging, Milan, Italy) and gadoterate meglumine (DOTAREM, Guerbet, Fr... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-005249-13 | Sponsor Protocol Number: Primovist - OATP1B1 | Start Date*: 2007-01-31 | |||||||||||
Sponsor Name:Department of Clinical Pharmacology, University of Greifswald | |||||||||||||
Full Title: Influence of the OATP1B1 genotype on the hepatic uptake of Primovist® in healthy volunteers and in patients with liver disease | |||||||||||||
Medical condition: The trial will be performed in 32 healthy subjects and in 60 patients with a liver disease subjected to MR imaging | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-000206-23 | Sponsor Protocol Number: MH-123 | Start Date*: 2009-09-15 | |||||||||||
Sponsor Name:BRACCO IMAGING | |||||||||||||
Full Title: PHASE IV, DOUBLE-BLIND, MULTI-CENTER, RANDOMIZED, CROSSOVER STUDY TO COMPARE 0.1 mmol/kg OF MULTIHANCE WITH 0.1 mmol/kg OF GADOVIST IN MAGNETIC RESONANCE IMAGING (MRI) OF THE BRAIN (MERIT) | |||||||||||||
Medical condition: Subjects with confirmed or highly suspected brain tumor(s) (primary or secondary) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003215-21 | Sponsor Protocol Number: DGD-44-063 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:GUERBET | |||||||||||||
Full Title: DOTAREM® Pharmacokinetics, Safety and Efficacy Study in Pediatric Subjects Aged <2 Years (Term Newborn Infants to Toddlers 23 Months of Age Inclusive) | |||||||||||||
Medical condition: Pediatric subject aged <2 years (term newborn infants to toddlers 23 months of age inclusive) scheduled to undergo routine gadolinium-enhanced Magnetic Resonance Imaging of any body region | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) HU (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-001680-33 | Sponsor Protocol Number: MH-130 | Start Date*: 2006-06-23 | |||||||||||
Sponsor Name:BRACCO IMAGING | |||||||||||||
Full Title: Phase IV, Double-blind, Multi-center, Randomized, Cross-over Study to Compare 0.10 mmol/kg of MultiHance R with 0.10 mmol/kg of Omniscan R in Magnetic Resonance Imaging MRI of the Brain | |||||||||||||
Medical condition: patients sent to the sites with a request for assessment/diagnoses of certain/suspected brain neoplasms | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-000079-38 | Sponsor Protocol Number: DB-OTO-001 | Start Date*: 2023-05-09 | |||||||||||
Sponsor Name:Decibel Therapeutics | |||||||||||||
Full Title: A Phase 1/2, Open-Label, Multicenter Trial With a Single Ascending Dose Cohort With Unilateral Intracochlear Injection Followed by a Bilateral Injection Expansion Cohort to Evaluate the Safety, Tol... | |||||||||||||
Medical condition: Congenital auditory neuropathy secondary to biallelic mutations of the otoferlin gene (hOTOF) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001599-12 | Sponsor Protocol Number: ASC-Man-P016 | Start Date*: 2019-10-21 | |||||||||||
Sponsor Name:Ascelia Pharma AB | |||||||||||||
Full Title: A Multicenter, Open-label Study to Evaluate the Safety and Diagnostic Efficacy of Mangoral in Patients with Known or Suspected Focal Liver Lesions and Severe Renal Impairment | |||||||||||||
Medical condition: MRI in terms of visualization of detected focal liver lesions in patients with known or Suspected focal liver lesions and severe renal impairment | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) SE (Ongoing) PL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
